Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer

This study has been completed.
ImClone LLC
Bristol-Myers Squibb
Information provided by (Responsible Party):
New York University School of Medicine Identifier:
First received: March 7, 2007
Last updated: January 25, 2016
Last verified: January 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2015
  Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)